Wednesday, 18 Oct 2017

You are here

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

  1. Biologics makes for ~90% of cost of RA care - infusions cost/Yr RTX $36,663; TCZ $36,821, INFLX $4,973; ABA $46,532 https://t.co/HJNaVh4A5m
  2. EU/EMA follows FDA decision to approve Orencia (abatacept) for use in active psoriatic arthritis as mono or combo Rx https://t.co/RkxRsGKahQ
  3. NIH/NIAID phase I & II trial of MV-CHIKV, a recombinant, live-attenuated measles vax expressing chikungunya proteins https://t.co/UjAQelwz8r
  4. Retrospective study 1171 ANCA+ vasculitis shows 16% w/ inflamm ocular disease – Half with eye pain, 16% visuall loss: Scleritis 22% episcleritis 21%, Uveitis 9%  https://t.co/qqrXgaLkBf
  5. RCT shows ustekinumab or guselkumab does NOT significantly reduce the signs and symptoms of RA. https://t.co/14N8ZsKbZ3
  6. Discrepancy between ultrasound and DECT quantification of urate tophi in gout joints; lower sensitivity with DECT https://t.co/RL5Vkq6GSz
  7. Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis https://t.co/emo6Te0yyW
  8. Biosimilar Pricing Wars Have Begun  
  9. Baricitinib Derailed by FDA Review
  10. Benlysta FDA Approved for Sub-Q Use in Lupus 
  11. Increased Pulmonary Embolism Risk in Lupus Patients  

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.